

5-9-05

614
\$P.T.O./SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

| | | |
|--|----------------------|---|
| Total Number of Pages in This Submission | Application Number | 10/016,146 |
| | Filing Date | December 10, 2001 |
| | First Named Inventor | Jay Cunningham |
| | Art Unit | 1614 |
| | Examiner Name | Phyllis G. Spivack |
| Attorney Docket Number | | 3078/04/US 31104/USA (6794-000094/COC) |

ENCLOSURES (check all that apply)

| | | |
|--|--|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form HDP-1449 46 References Return Receipt Postcard |
| <div>Remarks</div> | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | | | |
|--------------|----------------------------------|----------|--------|
| Firm | Harness, Dickey & Pierce, P.L.C. | | |
| Signature | | | |
| Printed Name | Lydia N. Nenow | | |
| Date | May 6, 2005 | Reg. No. | 52,530 |

CERTIFICATE OF TRANSMISSION/MAILING


I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

| | | | |
|-----------------------|----------------|------------------------|-----------------|
| Typed or printed name | Lydia N. Nenow | Express Mail Label No. | EV 726255925 US |
| Signature | | Date | May 6, 2005 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 726255925 US

**FEE TRANSMITTAL
for FY 2005**

Effective 10/01/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180**Complete If Known**

| | |
|----------------------|--------------------|
| Application Number | 10/016,146 |
| Filing Date | December 10, 2001 |
| First Named Inventor | Jay Cunningham |
| Examiner Name | Phyllis G. Spivack |
| Art Unit | 1614 |
| Attorney Docket No. | 3078/4/US |

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit card ☐ Money ☐ Other ☐ None
Order☐ Deposit Account:Deposit
Account
Number
08-0750Deposit
Account
Name
Harness, Dickey & Pierce, P.L.C.

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) or any underpayment of fees under 37 CFR 1.16 and 1.17
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

| Large Entity | | Small Entity | | Fee Description | Fee Paid |
|--------------|----------|--------------|----------|------------------------|----------|
| Fee Code | Fee (\$) | Fee Code | Fee (\$) | | |
| 1011 | 300 | 2011 | 150 | Utility filing fee | |
| 1012 | 200 | 2012 | 100 | Design filing fee | |
| 1013 | 200 | 2013 | 100 | Plant filing fee | |
| 1014 | 300 | 2014 | 150 | Reissue filing fee | |
| 1005 | 200 | 2005 | 100 | Provisional filing fee | |
| SUBTOTAL (1) | | | | | (\$) 0 |

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

| | | | | | | | | |
|--------------------|--|--------|---|---|---|--|---|---|
| Total Claims | | -20 ** | = | 0 | X | | = | 0 |
| Independent Claims | | -3 ** | = | 0 | X | | = | 0 |
| Multiple Dependent | | | | | | | = | 0 |

| Large Entity | | Small Entity | | Fee Description | Fee Paid |
|--------------|----------|--------------|----------|--|----------|
| Fee Code | Fee (\$) | Fee Code | Fee (\$) | | |
| 1202 | 50 | 2202 | 25 | Claims in excess of 20 | |
| 1201 | 200 | 2201 | 100 | Independent claims in excess of 3 | |
| 1203 | 360 | 2203 | 180 | Multiple dependent claim, if not paid | |
| 1204 | 200 | 2204 | 100 | ** Reissue independent claims over original patent | |
| 1205 | 50 | 2205 | 25 | ** Reissue claims in excess of 20 and over original patent | |
| SUBTOTAL (2) | | | | | (\$) 0 |

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

| Large Entity | | Small Entity | | Fee Description | Fee Paid |
|--------------|----------|--------------|----------|--|----------|
| Fee Code | Fee (\$) | Fee Code | Fee (\$) | | |
| 1051 | 130 | 2051 | 65 | Surcharge - late filing fee or oath | |
| 1052 | 50 | 2052 | 25 | Surcharge - late provisional filing fee or cover sheet. | |
| 1053 | 130 | 1053 | 130 | Non-English specification | |
| 1812 | 2,520 | 1812 | 2,520 | For filing a request for reexamination | |
| 1804 | 920* | 1804 | 920* | Requesting publication of SIR prior to Examiner action | |
| 1805 | 1,840* | 1805 | 1,840* | Requesting publication of SIR after Examiner action | |
| 1251 | 120 | 2251 | 60 | Extension for reply within first month | |
| 1252 | 450 | 2252 | 225 | Extension for reply within second month | |
| 1253 | 1020 | 2253 | 510 | Extension for reply within third month | |
| 1254 | 1,590 | 2254 | 795 | Extension for reply within fourth month | |
| 1255 | 2,160 | 2255 | 1080 | Extension for reply within fifth month | |
| 1401 | 500 | 2401 | 250 | Notice of Appeal | |
| 1402 | 500 | 2402 | 250 | Filing a brief in support of an appeal | |
| 1403 | 1000 | 2403 | 500 | Request for oral hearing | |
| 1452 | 500 | 2452 | 250 | Petition to revive - unavoidable | |
| 1453 | 1500 | 2453 | 750 | Petition to revive - unintentional | |
| 1501 | 1400 | 2501 | 700 | Utility issue fee (or reissue) | |
| 1502 | 800 | 2502 | 400 | Design issue fee | |
| 1460 | 130 | 1460 | 130 | Petitions to the Commissioner | |
| 1807 | 50 | 1807 | 50 | Processing fee under 37 CFR 1.17 (q) | |
| 1806 | 180 | 1806 | 180 | Submission of Information Disclosure Stmt | 180 |
| 8021 | 40 | 8021 | 40 | Recording each patent assignment per property (times number of properties) | |
| 1809 | 790 | 2809 | 395 | Filing a submission after final rejection (37 CFR § 1.129(a)) | |
| 1810 | 790 | 2810 | 395 | For each additional invention to be examined (37 CFR § 1.129(b)) | |
| 1801 | 790 | 2801 | 395 | Request for Continued Examination (RCE) | |

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid **SUBTOTAL (3)** (\$180)**4. SEARCH/EXAMINATION FEES**

| | | | | | |
|--------------|-----|------|-----|-------------------------|--------|
| 1111 | 500 | 2111 | 250 | Utility Search Fee | |
| 1112 | 100 | 2112 | 50 | Design Search Fee | |
| 1113 | 300 | 2113 | 150 | Plant Search Fee | |
| 1114 | 500 | 2114 | 250 | Reissue Search Fee | |
| 1311 | 200 | 2311 | 100 | Utility Examination Fee | |
| 1312 | 130 | 2312 | 65 | Design Examination Fee | |
| 1313 | 160 | 2313 | 80 | Plant Examination Fee | |
| 1314 | 600 | 2314 | 300 | Reissue Examination Fee | |
| SUBTOTAL (4) | | | | | (\$) 0 |

SUBMITTED BY

| | | | | | |
|-------------------|----------------|--------------------------------------|-------------|-----------|--------------|
| Name (Print/Type) | Lydia N. Nenow | Registration No. (Attorney/Agent) | 52,530 | Telephone | 314-726-7503 |
| Signature | | Date | May 6, 2005 | | |

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

EV 726255925 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jay Cunningham, et al.
Serial No: 10/016,146
Filed: December 10, 2001
Title: $\alpha_v\beta_3$ Integrin Antagonists in Combination with Chemotherapeutic Agents
Confirmation No: 7806
Group Art Unit: 1614
Examiner: Phyllis G. Spivack
Attorney Ref: 3078/US/04
Pfizer Ref: 31104/USA
HDP Ref: 6794-000094/COC

May 6, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 C.F.R. §1.97 and §1.98, Applicants have enclosed Form 1449 and all references cited on that form with the exception of the U.S. patents. In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form 1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art.


Applicants intend no representation that the listed documents represent the results of a

complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

This application is a continuation of U.S. Application Serial No. 09/262,725 (filed March 4, 1999, issued as U.S. Patent No. 6,372,719), which, in turn, is a continuation-in-part of U.S. Application Serial No. 09/034,270 (filed March 4, 1998, now abandoned). Applicants presume that the Examiner has access to the file histories for the above-referenced applications. Applicants further presume that the Examiner is aware of the issues raised and the scope of claims in those cases, and will take them into account when examining this patent application. Upon request from the Examiner, Applicants can provide copies of the substantive Office actions or any other information relating to those cases, to the extent Applicants have such information in their possession.

With respect to patent application publication DE 43 38 944 A1 (reference 15 in Form 1449), see patent application publication South Africa 94/9017 (reference 25 in Form 1449), which claims priority to DE 43 38 944, and is published in English.

The October 1, 2004 Office action requested the structure for the compound cited as "S448" in Nickols et al., "Antiangiogenic and anticancer activities of antagonists of integrin $\alpha_v\beta_3$ " published in Proceedings of the American Association of Cancer Research, Volume 38 (March 1997). It is Applicants' understanding that that compound corresponds in structure to the following formula:



Information Disclosure Statement
Appl. No. 10/016,146
May 6, 2005

Applicants request early and favorable consideration of this application.

* * * * *

Applicants have enclosed a check for \$180.00 to cover the fee for filing this supplemental information disclosure statement. Applicants do not believe that they owe any other fee in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge such fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



Lydia N. Nenow, PTO Reg. No. 52,530
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

Information Disclosure Statement
Appl. No. 10/016,146
May 6, 2005




CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **May 6, 2005** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.

A handwritten signature in cursive script, appearing to read "L. Nenow".

Lydia N. Nenow

LNN/JPG/CML



FORM 1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 4

ATTORNEY DOCKET No.

3078/4/US 31104/USA
(6794-000094/COC)

SERIAL No.

10/016,146

APPLICANT

Cunningham, et al.

FILING DATE

December 10, 2001

GROUP

1614

U.S. PATENT DOCUMENTS

| Ref. Desig. | Examiner's Initials | Document Number | Date | Name | Class/ Subclass | (If appropriate) Filing Date |
|-------------|---------------------|-----------------|----------|---------------------|-----------------|------------------------------|
| 1. | | 4,677,111 | 6/30/87 | Haga, et al. | 514/274 | |
| 2. | | 5,256,812 | 10/26/93 | Alig, et al. | 560/035 | |
| 3. | | 5,518,732 | 5/21/96 | Sturzbecher, et al. | 424/449 | |
| 4. | | 5,753,230 | 5/19/98 | Brooks | 424/158.1 | |
| 5. | | 5,766,591 | 6/16/98 | Brooks | 424/184.1 | |
| 6. | | 6,013,651 | 1/11/00 | Rogers | 514/269 | |

FOREIGN PATENT DOCUMENTS


| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translation Yes | No |
|-------------|---------------------|-----------------|----------|-----------|-----------------|-----------------|----|
| 7. | | AU-A-79090/94 | 6/8/95 | Australia | | | |
| 8. | | AU-A-57984/94 | 10/6/94 | Australia | | | |
| 9. | | 2,059,857 | 7/25/92 | Canada | | | |
| 10. | | 2,134,418 | 4/29/95 | Canada | | | |
| 11. | | EP 0 343 893 A1 | 11/29/89 | EPO | | | |
| 12. | | EP 0 343 894 A1 | 11/29/89 | EPO | | | |
| 13. | | EP 0 478 328 A1 | 4/1/92 | EPO | | | |
| 14. | | EP 0 478 363 A2 | 4/1/92 | EPO | | | |
| 15. | | DE 43 38 944 A1 | 5/18/95 | Germany | | | X |
| 16. | | WO 95/32710 | 12/7/95 | PCT | | | |
| 17. | | WO 98/31359 | 7/23/98 | PCT | | | |
| 18. | | WO 95/28426 | 10/26/95 | PCT | | | |

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 726255925 US




| | | |
|---|--|------------|
| FORM HD-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 4 | ATTORNEY DOCKET No. | SERIAL No. |
| | 3078/4/US 31104/USA (6794-000094/COC) | 10/016,146 |
| | APPLICANT | |
| | Cunningham, et al. | |
| | FILING DATE | GROUP |
| | December 10, 2001 | 1614 |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|---------------------|-----------------|----------|--------------|-----------------|-----------------|----|
| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translation Yes | No |
| 19. | | WO 95/14714 | 6/1/95 | PCT | | | |
| 20. | | WO 98/14192 | 4/9/98 | PCT | | | |
| 21. | | WO 93/08823 | 5/13/93 | PCT | | | |
| 22. | | WO 97/08145 | 3/6/97 | PCT | | | |
| 23. | | WO 96/00730 | 1/11/96 | PCT | | | |
| 24. | | WO 96/00574 | 1/11/96 | PCT | | | |
| 25. | | 94/9017 | 11/14/94 | South Africa | | | |
| 26. | | 94/2124 | 3/25/94 | South Africa | | | |
| 27. | | 94/0435 | 1/21/94 | South Africa | | | |

| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|---------------------|---|
| Ref. Desig. | Examiner's Initials | |
| 28. | | Adamis, et al., Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy, American Journal of Ophthalmology, Vol. 118 (1994) 445-450 |
| 29. | | Brooks, et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Antigenic Blood Vessels, Cell, Vol. 79 (1994) 1157-1164 |
| 30. | | Brooks, et al., Requirement for Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis, Science, Vol. 264 (1994) 569-571 |
| 31. | | Carter, et al., Chemotherapy of Cancer, Sec. Ed., John Wiley & Sons, NY, NY (1981) 107-108 |
| 32. | | Choi, et al., Inhibition of Neointimal Hyperplasia by Blocking $\alpha_v\beta_3$ Integrin with a Small Peptide Antagonist GpenGRDSPCA, Journal of Vascular Surgery, Vol. 19 (1) 125-134 |

| | |
|-----------|------------------|
| Examiner: | Date Considered: |
|-----------|------------------|

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 3 of 4

ATTORNEY DOCKET NO.

3078/4/US 31104/USA
(6794-000094/COC)

SERIAL NO.

10/016,146

APPLICANT

Cunningham, et al.

FILING DATE

December 10, 2001

GROUP

1614


OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

| Ref. Desig. | Examiner's Initials | |
|-------------|---------------------|---|
| 33. | | Clyman, et al., β_1 and β_3 Integrins Have Different Roles in the Adhesion and Migration of Vascular Smooth Muscle Cells on Extracellular Matrix, Experimental Cell Research, Vol. 200, (1992) 272-284 |
| 34. | | Fields, Integrins: Cell Adhesion Molecules in Cancer, Exp. Opin. Ther. Patents, Vol. 8 (No. 6), (1998) 633-644 |
| 35. | | Hong, et al., Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching, J. Med. Chem., American Chemical Society, v. 40 (1997) 930-936 |
| 36. | | Liaw, et al., The Adhesive and Migratory Effects of Osteopontin Are Mediated Via Distinct Cell Surface Integrins: Role of a $\alpha_v\beta_3$ in Smooth Muscle Migration to Osteopontin in Vitro, Journal of Clinical Investigation, Vol. 95 (1995) 713-724 |
| 37. | | Derwent Abstract 1987-009150/198702 |
| 38. | | Derwent Abstract 1987-065042/198710 |
| 39. | | Derwent Abstract 1989-055466/198908 |
| 40. | | Derwent Abstract 1989-349943/198948 |
| 41. | | Derwent Abstract 1992-398070/199248 |
| 42. | | Derwent Abstract 1993-060253/199308 |
| 43. | | Derwent Abstract 1993-127579/199316 |
| 44. | | Nicklaus, et al., HIV-1 Integrase Pharmacophore: Discovery of Inhibitors Through Three-Dimensional Database Searching, J. Med. Chem. v. 40 (1997) 920-929 |
| 45. | | Peacock, et al., Angiogenesis Inhibition Suppresses Collagen Arthritis, Journal of Experimental Medicine, Vol. 175 (1992) 1135-1138 |
| 46. | | Pommier, et al., HIV-1 Integrase as Target for Antiviral Drugs, Antiviral Chemistry & Chemotherapy, Vol. 8 (No. 6) (1997) 463-483 |
| 47. | | Schnur, et al., N-(5-Fluorobenzothiazol-2-yl)-2-guanidinothiazone-4-carboxamide. A Novel, Systematically Active Antitumor Agent Effective Against 3LL Lewis Lung Carcinoma, Journal of Medicinal Chemistry, Vol. 34 (3) (1991) 914-918 |

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



| | | |
|--|--|------------|
| FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 4 of 4 | ATTORNEY DOCKET No. | SERIAL No. |
| | 3078/4/US 31104/USA (6794-000094/COC) | 10/016,146 |
| | APPLICANT | |
| | Cunningham, et al. | |
| | FILING DATE | GROUP |
| | December 10, 2001 | 1614 |

| OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) | | |
|--|---------------------|---|
| Ref. Desig. | Examiner's Initials | |
| 48. | | Schnur, et al., Quantitative Structure-Activity Relationships of Antitumor Guanidinothiazolecarboxamides with Survival Enhancement for Therapy in the 3LL Lewis Lunch Carcinoma Model, Journal of Medicinal Chemistry, Vol. 34 (7) (1991) 1975-1982 |
| 49. | | Seftor, et al., Role of the $\alpha_v\beta_3$ Integrin in Human Melanoma Cell Invasion, Proceedings of the National Academy of Sciences U.S.A., Vol. 89 (1992) 1557-1561 |
| 50. | | Smith, et al., Interactions of Integrins $\alpha_v\beta_3$ and GlycoProtein IIb-IIIa with Fibrinogen, Journal of Medicinal Chemistry, Vol. 265 (21) (1990) 12267-12271 |
| 51. | | White, Integrins as Virus Receptors, Current Biology, Vol. 3 (9) (1993) 596-599 |
| 52. | | Yue, Osteopontin-Stimulated Vascular Smooth Muscle Cell Migration is Mediated by $\alpha_v\beta_3$ Integrin, Experimental Cell Research, Vol. 214 (1994) 459-464 |

| | |
|-----------|------------------|
| Examiner: | Date Considered: |
|-----------|------------------|

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.